Chimeric Antigen Receptor T Cell Therapy for Acute Leukemia

Area of Science:

• Hematology
• Immunotherapy
• Oncology

Background:

• Chimeric antigen receptor (CAR)-T cell therapy has significantly improved response rates in refractory or relapsed B-cell acute lymphoblastic leukemia.
• Established guidelines and interventions like tocilizumab and steroids manage immunotherapy-related toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

Purpose of the Study:

• To review current advancements in CAR-T cell therapy for hematologic malignancies, focusing on toxicity management, overcoming treatment challenges, and addressing relapse.
• To highlight emerging strategies for managing severe CRS and ICANS, improving CAR-T cell efficacy in heavily pretreated patients, and preventing relapse.

Main Methods:

• Review of current clinical practices and emerging research in CAR-T cell therapy for B-cell acute lymphoblastic leukemia and other hematologic malignancies.
• Analysis of interventions for managing CRS and ICANS, including novel drug combinations and procedural techniques.
• Exploration of strategies to address CAR-T cell therapy challenges such as manufacturing, expansion, relapse, and T-lineage CAR-T cell fratricide.

Main Results:

• The combination of ruxolitinib and steroids effectively controlled severe CRS without hindering CAR-T cell expansion.
• Intracranial steroid injections and Ommaya capsule implantation showed efficacy in managing CNS complications.
• Combination therapies, including blinatumumab, allogeneic stem cell transplantation, dual-target CAR-T cells, and sequential CD19/22 CAR-T infusions, are being investigated to improve outcomes and prevent relapse.
• CD7+ CAR-T cell therapy shows promise with high response rates, but careful monitoring for infections and relapse is crucial, necessitating strategies for target switching and elimination of residual CAR-T cells.

Conclusions:

• CAR-T cell therapy continues to evolve, with significant progress in managing toxicities and improving patient responses.
• Ongoing research focuses on overcoming challenges like relapse and enhancing efficacy through combination strategies and novel CAR constructs.
• Further investigation is needed, particularly for CAR-T cell therapies in acute myeloid leukemia, with specific attention to patient populations and fusion genes.